NCT03270280

Brief Summary

Periodontitis is an infectious inflammatory disease affecting the periodontal tissue (Gingivae, alveolar bone, periodontal ligament and cementum). Chronic Periodontitis is considered to be the most prevalent disease after dental caries which is linked to increased levels of C- reactive protein, interleukins and matrix metallo-proteinases. Interleukin- 1β and Matrix metalloproteinase-8 have been shown to be robust markers of inflammatory cascade of chronic periodontitis.Various treatment modalities including scaling and root planing, toothpastes and chlorhexidine based mouthwashes have been are known to be associated with various side effects like teeth staining, altered taste sensation, mucosal burning. Hence,the use of natural medicaments could provide a better alternative because of their fewer side effects and cost effectiveness.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
25

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Sep 2017

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 29, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 1, 2017

Completed
10 days until next milestone

Study Start

First participant enrolled

September 11, 2017

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 11, 2018

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

April 11, 2018

Completed
Last Updated

September 1, 2017

Status Verified

August 1, 2017

Enrollment Period

6 months

First QC Date

August 29, 2017

Last Update Submit

August 31, 2017

Conditions

Keywords

Chronic PeriodontitisPhytomedicinesNigella sativa

Outcome Measures

Primary Outcomes (1)

  • Levels of IL 1-Beta and MMP-8

    These inflammatory marker will be measured in patients saliva again after 2 weeks. There will be reduction in their levels.

    2 weeks

Study Arms (2)

Normal Saline

PLACEBO COMPARATOR

The group contains healthy individuals with chronic periodontitis who will receive Normal Saline as placebo

Drug: Normal saline

Nigella Sativa

EXPERIMENTAL

The group contains healthy individuals with chronic periodontitis who will receive Nigella sativa Oil as intervention

Drug: Nigella Sativa Oil

Interventions

The individuals will apply 55 drops of Nigella sativa Oil on gingivae twice daily for two weeks

Also known as: Black seed Oil
Nigella Sativa

The individuals will apply 55 drops of Normal saline on gingivae twice daily for two weeks

Also known as: Saline
Normal Saline

Eligibility Criteria

Age19 Years - 40 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Male and female healthy individual
  • Individuals diagnosed with chronic periodontitis according to the WHO criteria.
  • Age 19 to 40 years.

You may not qualify if:

  • Patients with gingivitis only.
  • Patients using tobacco products and alcohol.
  • Underlying systemic pathology such as diabetes mellitus, cardiovascular disease, arthritis etc.
  • Oral mucosal pre-neoplastic lesions (leukoplakia, erthroplakia, lichen planus) and oral carcinomas.
  • Obese patients.
  • Pregnant females.
  • Xerostomia.
  • Previous history of radiotherapy or chemotherapy.
  • Positive history of oral prophylactic procedures (mouthwashes and antibiotics).
  • Positive history of any periodontal treatment during last 6 months.
  • Positive antibiotic therapy history within last month of study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Fatima Memorial Hospital

Lahore, Punjab Province, 0092, Pakistan

Location

Related Publications (2)

  • Zadik Y, Bechor R, Galor S, Levin L. Periodontal disease might be associated even with impaired fasting glucose. Br Dent J. 2010 May 22;208(10):E20. doi: 10.1038/sj.bdj.2010.291. Epub 2010 Mar 26.

    PMID: 20339371BACKGROUND
  • Gupta N, Gupta ND, Gupta A, Khan S, Bansal N. Role of salivary matrix metalloproteinase-8 (MMP-8) in chronic periodontitis diagnosis. Front Med. 2015 Mar;9(1):72-6. doi: 10.1007/s11684-014-0347-x. Epub 2014 Aug 6.

    PMID: 25098434BACKGROUND

MeSH Terms

Conditions

Chronic Periodontitis

Interventions

Nigella sativa oilSaline SolutionSodium Chloride

Condition Hierarchy (Ancestors)

PeriodontitisPeriodontal DiseasesMouth DiseasesStomatognathic DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Crystalloid SolutionsIsotonic SolutionsSolutionsPharmaceutical PreparationsChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Ghazala Hassan, MPhil

    Research Scholar

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ghazala Hassan, MPhil

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
Triple Blind
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Model Details: Healthy Individuals with Chronic Periodontitis Only
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Research Scholar

Study Record Dates

First Submitted

August 29, 2017

First Posted

September 1, 2017

Study Start

September 11, 2017

Primary Completion

March 11, 2018

Study Completion

April 11, 2018

Last Updated

September 1, 2017

Record last verified: 2017-08

Data Sharing

IPD Sharing
Will not share

Data sharing will be considered after the completion of studies

Locations